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Mutations of the AGXT gene encoding the alanine:glyoxylate aminotransferase liver enzyme 
(AGT) cause primary hyperoxaluria type 1 (PH1). Here we report a molecular modeling study of 
selected missense AGXT mutations: the common Gly170Arg, the recently described Gly47Arg 
and Ser81Leu variants, predicted to be pathogenic using standard criteria. 
Methods 
 
Taking advantage of the refined 3D structure of AGT, we computed the dimerization energy of 
the wild type and mutated proteins. 
Results 
 
Molecular modeling predicted that Gly47Arg affects dimerization with a similar effect to that 
shown previously for Gly170Arg through classical biochemical approaches. In contrast, no effect 
on dimerization was predicted for Ser81Leu. Therefore, this probably demonstrates pathogenic 
properties  via  a  different  mechanism,  similar  to  that  described  for  the  adjacent  Gly82Glu 
mutation that affects pyridoxine binding. 
Conclusion 
 
This study shows that the molecular modeling approach can contribute to evaluating the 
pathogenicity of some missense variants that affect dimerization. However, in silico studies - 
aimed to assess the relationship between structural change and biological effects - requires the 












Primary hyperoxaluria type I (PH1) is an autosomal recessive disorder caused by defects of the 
liver-specific peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT, EC 2.6.1.44) 
encoded by the AGXT gene (1). The AGT molecule has a homodimeric structure of 2x43 kD/ 392 
aminoacid subunits. AGT rapidly dimerizes after synthesis in the cytosol, and is imported into the 
peroxisomes, where it catalyzes the transamination of glyoxylate to glycine, coupled with the 
conversion of alanine to pyruvate, with pyridoxal-5-phosphate as a cofactor. 
Deficiency of AGT in PH1 patients impairs the hepatic detoxification of glyoxylate and results in 
increased oxalate and glycolate in plasma and urine. Excess oxalate saturates body fluids and 
accumulates as insoluble calcium salts in several organs (2, 3). The natural history of untreated 
PH1 is characterized by progressive decline in renal function, from nephrolithiasis 
nephrocalcinosis to generalized oxalosis and death (4). 
A comprehensive algorithm for the clinical and biochemical diagnosis of hyperoxaluria has been 
recently proposed (5). AGXT gene testing has become an important diagnostic tool (6-8) and 
provided that the pathogenicity of mutations is verified, it renders the invasive liver biopsy (for 
direct assaying of AGT activity) unnecessary in most cases (9). Conversely, when only private 
variants of unknown pathogenicity are found, molecular diagnosis remains doubtful. 
The mutational spectrum of the AGXT gene encompasses almost 100 different mutations so far, 
including nonsense, splice site, frameshift and missense point mutations, and rarer entire exon 
deletions  (6,8,10). Missense mutations may have various pathogenic effects. The most frequent, 
Gly170Arg, causes a remarkable trafficking defect, whereby the newly synthesized AGT subunit 
is diverted away from its normal peroxisomal location, in part degraded, while the remaining in 
part is diverted to the mitochondria where eventually dimerizes (11). This effect is synergistically 
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influenced by the common Pro11Leu polymorphism whose Leu allele introduces a mitochondrial 
signal sequence (12), that targets a fraction of the AGT protein to the mitochondrion (13), and 
decreases the enzyme activity by 30% (14). Docking of the correctly folded monomers into stable 
dimers represents a critical step of AGT biosynthesis. Patients carrying Gly170Arg, or other 
mistargeting mutations synergic with the Leu11, like Phe152Ile (14), are most likely to respond 
to vitamin B6 (Pyridoxine) (16-18). Other missense mutations are associated with accelerated 
degradation or intra-peroxisomal aggregation, that probably result from misfolding at later stages 
of AGT biosynthesis (14). Finally, specific mutations of critical residues in the catalytic- or the 
cofactor-binding sites can affect the enzymatic activity without altering AGT dimerization or 
targeting (19). 
Determination of the crystal structure of the AGT enzyme has enabled us to improve the 
understanding  of  the  pathogenic  effects  of  some  recurrent  missense  mutations,  in  terms  of 
folding, dimerization and stability (20). Such studies may open the way to new therapeutic 
strategies, based on the structure-based design of small molecules capable of rescuing the 
defective enzyme, and thus extending the chance of conservative treatment to other more severe, 
life-threatening and non-Pyridoxine responsive mutations (21). 
In this paper we approach the question by using a new in silico molecular modeling method 
aimed to rationalize the effects of specific missense AGT mutations on dimerization 




SUBJECTS AND METHODS 
 
Patients in whom the modeled mutations were identified belong to the Italian multicenter study of 
primary Hyperoxaluria, and had given their informed consent to use their genetic and clinical 
data for research purposes, as already described  (17,22). Age at onset, relevant clinical data and 
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residual liver AGT activity, when available, are shown in Table 1. Screening of AGXT gene 
mutations was performed on genomic DNA through PCR amplification and direct sequencing, 
whereas healthy controls were analysed by DHPLC. The refseq NP_000021.1 protein sequence 
of the human AGT gene was used as reference. Multiple sequence alignment of 22 orthologous 
species was generated using ClustalW (http://www.ebi.ac.uk/Tools/clustalw2/index.html, 
Supplementary material, Fig.2). The evolutionary conservation at the mutated positions was 
evaluated using the SIFT (23), SNPs3D (24) and PMUT (25) algorithms available on line. The 
“major” or “minor” haplotype were characterized by inspection of the relevant sequence features 
at codons 11 and 340  (26). 
Molecular Modeling. Starting from the crystal structure of the wt AGT homodimer WT:WT  (20) 
we prepared the refined three-dimensional (3D) structure of the wild type (wt) dimer bound to the 
pyridoxal-5’-phosphate (PLP) cofactor and the aminooxyacetic acid (AOA) inhibitor (Figure 1) 
available from Protein Data Bank (27) - and from there we prepared the structure of the wt AGT 
monomer. 
In the 3D models of the mutant AGT forms (mt) we replaced the side chains at the mutated sites 
by the best rotamer of the substituting residue followed by careful conformational search and 
geometry optimization using the molecular modeling software Insight-II (Accelrys Software Inc., 
San Diego, CA, release 2000). We computed the conformational and interaction energies of each 
AGT monomer and dimer by molecular mechanics (MM) using class II consistent force field 
CFF91 and charge parameters (28). 
The dimerization of two mt AGT monomers in aqueous solution to form a homodimer (MT:MT) 
can be represented by the energy of dimerization: ∆Etot = Etot[MT:MT] - 2Etot[MT], composed of 
contributions  from  molecular mechanics  (MM)  potential  energy  (∆EMM)  and  solvent  effects 
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(∆Esolv) as: ∆Etot  = ∆EMM  + ∆Esolv. When computing dimerization energy, we took into account 
the interaction between monomers in the dimer, the stability and molecular structure of the free 
monomers and the effect of solvent upon monomers association. We compared the different mt 
AGT  forms  via  relative  changes  in  the  dimerization  energy,  ∆∆Etot    =  ∆Etot[MT:MT]  - 
∆Etot[WT:WT]  with  respect  to  the  reference  wt  homodimer  WT:WT.  Relative  changes  were 
 
defined in a similar way for the contributions of both the MM interaction energy and the solvent 
effect. 
When computing the solvation energy, we also incorporated the effects of ionic strength through 
the solution of nonlinear Poisson-Boltzmann equation (29), using the software package DelPhi 
(Accelrys Software Inc., San Diego, CA, release 2000). 
We calculated the molecular solvent-accessible surface area of the wt and mt residues by using 
the Connolly algorithm (30) implemented in the Insight-II software. Relative changes in the 
accessible surface area of the studied residues upon dimer formation (∆∆Sbur) were calculated as 
a difference in the solvent accessible surfaces of residues in the dimer and in the free monomers 
with  respect  to  the  corresponding  residues  in  the  reference  wt  form  of  AGT:    ∆∆Sbur   = 






AGXT Mutations. The 3 selected mutations were all absent in 80 healthy ethnically-matched 
controls (160 chromosomes). Multiple sequence alignment showed evolutionary conservation at 
residue Gly47 and Gly170 in 22/22 species and at Ser81 in 17/22 (Supplementary material, 
Fig.2). The SIFT and SNPs3D software tools concordantly predicted Gly47Arg and Ser81Leu to 
be not tolerated, with similar or stronger scores than the common Gly170Arg mutation (Table 1), 
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and were considered as pathogenic. In contrast, the PMUT software predicted only Gly47Arg to 
be pathogenic, and Ser81Leu to be tolerated. 
We then implemented a molecular modeling approach to study the effect of the three missense 
changes on AGT dimerization, using the known Gly170Arg mutation as a positive control. For 
this, we modeled the homodimeric AGT forms of each of the three changes, as well as the 
heterodimer expected in the Gly170Arg/Gly47Arg compound heterozygous patient 1. No 
heterodimer was expected in patient 2 who carried a null mutation on the second allele. 
Molecular Modeling. Residue Gly47 is located on the dimerization interface of AGT, close to 
the C-terminal boundary of the long, irregular N-terminal coil (residues 1-21) that upon 
dimerization  wraps  around  the  cognate  monomer  (Figure  2).  Residue  Ser81  is  similarly 
positioned  on  the dimerization interface,  near the  cofactor  binding site.  In  contrast,  residue 
Gly170 is located on the exposed surface without direct contact with the cognate monomer. Due 
to its position at the dimer interface, the substitution of the small Gly47 residue by a bulky 
cationic Arginine contributes more to the relative surface area buried upon AGT dimerization 
(∆∆Sbur) than the other mutations that either insert a smaller residue or are located outside of the 
dimerization interface (Table 2). The Gly47Arg and Gly170Arg substitutions stabilize the AGT 
homodimers via increased monomer-monomer interaction, ∆∆EMM, more than the Ser81Leu 
substitution (Table 2). 
On the other hand, the attractive MM interactions caused by the non conservative Gly to Arg 
substitutions are largely compensated for upon AGT dimerization by the effect of the solvent. 
The wt AGT monomer bears a total molecular charge of +1e-, while Arg47 and Arg170 increase 
its charge to +2 e-. In both cases, and especially for Arg47, the free mt monomers with the 
 
charged Arg residues exposed to the solvent are better stabilized by the interactions with water 
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(∆∆Esolv) than the dimers, where the corresponding residues are partially buried (Table 2). Thus 
the stability of the mutated dimers is significantly diminished by the effect of protein hydratation. 
In contrast, the Ser81Leu substitution does not change the charge. The overall dimer stability, 
which takes into account both the interactions between the residues of the associated monomers 
and the solvent effect (∆∆Etot), is weaker for all the considered mt dimers than the native WT:WT. 
Our  computational  approach  predicts  a  stronger  decrease  of  dimer  stability  for  the  mt 
G47R:G47R > G170R:G170R dimers compared to the WT:WT reference, while only a minor 






The  pathogenic  effect  of  recurrent  AGT  mutations  has  been  extensively  investigated  with 
classical biochemical and biological approaches. A series of studies, both ex vivo and in vitro, 
have highlighted the peculiar effect of the recurrent Gly170Arg mutation on AGT biosynthesis 
(15).  However,  no  comparable  knowledge  is  available  for  the  remaining  missense  AGT 
mutations, about 30-34% in Caucasians, in which a growing series of rarer or private changes are 
identified (10). In these cases, the current criteria of cosegregation of disease in families and lack 
of disease in controls does not always allow to discriminate true mutations from rare 
polymorphisms. The liver specific expression of AGT further hampers to evaluate the effect of 
promoter and splice-control mutations on mRNA biosynthesis. For missense mutations, 
determination of the crystal structure of AGT has opened the way to rationalize the pathogenic 
mechanisms in terms of folding, dimerization and stability of the enzyme (20).  Here we describe 
the application of molecular modeling techniques as a means to explore the pathogenic potential 
of AGT missense mutations. Similar approaches was previously employed by Burnett et al (31) 
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for hemoglobin and Kobayashi et al  (32) for lipoprotein lipases, but to our knowledge their use 
for AGT mutations is novel. 
We assumed the working hypothesis that some mutations, in particular the Gly47Arg situated on 
the dimerization interface, affect the formation of AGT dimers and may exert effects similar to 
those demonstrated for Gly170Arg. Indeed, when we rationalized the stability of the mutated 
Gly170Arg and Gly47Arg dimers in terms of net charge and size of the replacing Arg residue and 
its location on the molecular surface with respect to the dimerization region, solvation resulted to 
exert a dominant effect and stabilize the free monomers more than the corresponding dimers. In 
our molecular modeling both mutations change the ∆∆Etot   by an order of tenth kcal·mol-1 , i.e. 
shift the equilibrium constant of the mt molecules from dimer to free monomeric mt. In other 
 
words, dimers with either mutation are predicted to be less thermodynamically stable at 
physiological conditions than the wild type AGT dimer. 
Decreased stability of the mutated AGT dimers has been previously considered as a possible 
cause of the peroxisomes-to-mitochondria mistargeting (15) and accelerated AGT degradation or 
aggregation that have been associated with the Gly170Arg mutation (14). According to our 
modeling study, Gly47Arg destabilizes the AGT dimer even more than Gly170Arg. Interestingly, 
a similar destabilizing effect is predicted for both the Gly170Arg:Gly170Arg and 
Gly47Arg:Gly47Arg mutated homodimers and for the Gly47Arg:Gly170Arg heterodimer, whose 
corresponding in vivo situation is represented by the compound heterozygous patient 1. On 
overall, these data support the pathogenicity of Gly47Arg, although its clinical severity cannot be 
established in the presence of the mild Gly170Arg mutation, as in general true for new described 
mutations when found in compound heterozygosity with mild ones. 
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The  effect  of  the  Ser81Leu  mutation  predicted  from  molecular  modeling  is  much  less 
pronounced, with a minimal change of the ∆∆Etot, suggesting that secondary structures and 
dimers formation are not affected. This  is in agreement with the PMUT results, based also on the 
profile of secondary structure and solvent accessibility. On the other hand, Ser81Leu should be 
considered pathogenic on the basis of absence in ethnically matched controls and high degree of 
evolutionary conservation. Its proximity to the cofactor and substrate binding sites suggests that it 
may affect the catalytic function of the enzyme. Indeed, the adjacent Gly82Glu mutation was 
previously described to affect pyridoxine binding (14). 
The wide mutational spectrum of primary hyperoxaluria and the consequent variety of the AGT 
enzyme defects makes the use of multiple approaches to characterize novel mutations highly 
recommended. Since dimerization represents a critical step in AGT biosynthesis, the presented 
approach  can  significantly  contribute  to  assess  the  pathogenicity  of  missense  mutations, 
clarifying their contribution to the phenotype and providing some insight into the structural and 
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Dimerization site/active site view of the relaxed wt AGT monomer in a ribbon rendering. 
The  co-factor  pyridoxal-5’-phosphate  (PLP)  and  the  substrate  aminooxyacetic  acid 
(AOA) are shown in Corey-Pauling-Kultun (CPK) representation in cyan and brown. The 
locations of the Leu11 and Met340 residues of the minor polymorphic form are indicated 
by horizontal and vertical arrows respectively. The mutated residues are highlighted: 






(A) Front view and (B) side view of the AGT dimer WT:WT in Corey-Pauling-Kultun 
(CPK) representation, with monomer A shown in red and monomer B in blue. Positions of 
the mutated residues GlyA47 and GlyB47 are shown in yellow, residues GlyA170 and 
GlyB170 in white. Residues SerA81 and SerB81 located at the dimerization interface are 
not visible. The long N-terminal extensions (coils of residues 1 – 21) wrap around the N- 
terminal segment of the opposing monomer. 



























































































































*  minor haplotype is defined by P11L + 74bp-duplication in intron 1 + I340M. 
 









Table 2. Buried surface and relative energies of dimerization of wild type (wt) and 
 































(Qwt = +1) f 
wt AGT 
(Qwt = +1) 






mt AGT Gly47Arg 
 
(Qmt = +2) 
mt AGT Gly47Arg 
 
(Qmt = +2) 






mt AGT Gly170Arg 
 
(Qmt = +2) 
mt AGT Gly170Arg 
 
(Qmt = +2) 






mt AGT Ser81Leu 
 
(Qmt = +1) 
mt AGT Ser81Leu 
 
(Qmt = +1) 






mt AGT Gly47Arg 
 
(Qmt = +2) 
mt AGT Gly170Arg 
 
(Qmt = +2) 
110 -19 74 55 
 
a 
∆∆Sbur  – relative contribution of mutated residue to the buried surface upon dimer 
formation  was  calculated  as  the  difference  in  Connolly  surfaces  (30)  of  the 
3  
concerned residues in the dimer MT:MT and in free monomer MT with respect to the 
native residues in the homodimer WT:WT ∆∆Sbur = (2SCon[mt]MT - SCon[mt,mt]MT:MT) 
– (2SCon[wt]WT - SCon[wt,wt]WT:WT), in [Å2]; 
 
b 
∆∆EMM = (EMM[MT:MT] - 2EMM[MT]) – (EMM[WT:WT] - 2EMM[WT]) is the relative 
molecular mechanics interaction energy contribution to the MT:MT AGT dimer 
formation with respect to the wt homodimer WT:WT; 
c 
∆∆Esolv = (Esolv[MT:MT] - 2Esolv[MT]) – (Esolv[WT:WT] - 2Esolv[WT]) is the relative 
solvation energy contribution to the MT:MT AGT dimer formation with respect to 
the wt homodimer WT:WT; 
d 
∆∆Etot  = ∆∆EMM  + ∆∆Esolv  is the relative total energy change connected with the 
 
MT:MT AGT dimer formation with respect to the wt homodimer WT:WT; 
 
e a change of ∆∆Etot by 10 kcal·mol-1 corresponds to about 3.2% change in the energy 
of dimerization the WT:WT dimer. For comparison, an increase of Gibbs free of a 
dimerization reaction by 10 kcal·mol-1 will cause a shift of the equilibrium constant 
of this reaction by a factor of 5·108 towards dissociated monomers; 
f Qwt, Qmt are the molecular charges of wt or mt AGT monomers including the co- 
 
factor PLP and substrate AOA. 

























Supplementary Material 1: Legend to Figure 1 
 











Supplementary Material 2. 
 
Multiple sequence alignment of AGT orthologous sequences of 22 different species. 
 
The four mutated residues are highlighted with boxes, and the substituting residue is indicated 
above the top line. The degree of evolutionary conservation of each residue is indicated below the 
bottom line, according to Clustal rules: * identity,  : conservative substitution, . semi-conservative 
substitution 
H.sapiens NP_000021.1, M.mulatta XP_001090301.1, P.pygmaeus Q5RDP0.1, C.jacchus 
P31029.1, C.familiaris XP_855949.1, F.catus NP_001036031.1, E.caballus 
XP_001497552.1, B.taurus NP_001095825.1, O.cuniculus NP_001075778.1, O.anatinus 
XP_001513675.1, R.norvegicus NP_085914.1, M.musculus NP_057911.2, X.laevis 
NP_001081948.1, D.rerio NP_001002331.1, D.melanogaster NP_511062.1, A.aegypti 
XP_001660875.1, N.vitripennis XP_001608017.1, A.mellifera XP_397119.2, C.elegans 
NP_495885.1, S.purpuratus XP_780986.2, Cyanothece sp. CCY0110 ZP_01727410.1, 
Prochlorococcus marinus str. NATL2A YP_291337.1 
 





C.jacchus ----------------------------------------------MFQALAKASAALGP 14 
Canis_familiaris ----------------------------------------------MFRALARASVALGP 14 
Felis_catus ----------------------------------------------MFRALARASATLGP 14 
Equus_caballus MPSQEAVADPGPPLLPCLPAACKGFCFLLTLQPLGLVWSRRGASREMLRALAMASVALGP 60
 




Mus_musculus ----------------------------------------------MFRMLAKASVTLGS 14 






C.elegans ---------------------------------------------------MISTRFLRP 9 
 S.purpuratus ------------------------------------------------------------ 
Cyanothece_bacter ------------------------------------------------------------ 
Pr.coccus_marinus ----------------------------------------MQSLKKTPRLCLSPFRLGRY 20 
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 Cyanothece_bacter VDMATRYGADVKTINKPWGENFSLAELKEAIETHKPAILGLVNAETSTGVRQP-LEGVGE 163 
Pr.coccus_marinus ADMAGRYKANVETIHKEWGNAFSLQEIEDALKKHTPAVLAIVHAETSTGVCQP-MDGIGD 199 
:. * * : :. . : * . : :.::* *: : : * 
 































































































































 :. :::** *.:: . . * :* *: :** :. *.* .::. * :  
 































































































































 :. * : * *** . : :* .: *  
 

























































































































 Pr.coccus_marinus RHRTNAKSLWNSLENIGLELHVK-EELRLPTLTTVKIPEGLDGKAFTKHLLNNFGVEIGG 373 
* :* : :: * . : *: 
 






















































































































































10  I 
















c.508G>A leading to p.Giy170Arg in patient 1 
c.139G>A leading to p.Giy47Arg in patient 1 
c.242C>T leading to p.Ser81Leu in patient 2 
